G. Starling

发表

Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo‐1) and Fas Ligand (CD178) expression

W. Hiddemann, T. Haferlach, P. Kiener, 2002, British journal of haematology.

Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells

D. Chao, Yuni Fang, Shiming Ye, 2017, Journal of immunology research.

B7/BB-1 is a leucocyte differentiation antigen on human dendritic cells induced by activation.

G. Starling, D. Hart, V. Calder, 1993, Immunology.

A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D.

L. Giot, Y. Halvorsen, P. Pochart, 2008, International journal of clinical pharmacology and therapeutics.

Activation of human peripheral blood dendritic cells induces the CD86 co‐stimulatory molecule

B. Hock, G. Starling, A. McLellan, 1995, European journal of immunology.

Identification of a Circulating Soluble Form of CD80: Levels in Patients with Hematological Malignancies

B. Hock, J. McKenzie, G. Starling, 2004, Leukemia & lymphoma.

Identification of purine inhibitors of phosphodiesterase 7 (PDE7).

J. Y. Roberge, J. Barrish, M. Poss, 2004, Bioorganic & medicinal chemistry letters.

Role of tumour necrosis factor-alpha in dendritic cell-mediated primary mixed leucocyte reactions.

J. McKenzie, G. Starling, D. Hart, 1995, Bone marrow transplantation.

Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis.

P. Boor, F. Eitner, J. Floege, 2006, Journal of the American Society of Nephrology : JASN.

BTNL8, a butyrophilin-like molecule that costimulates the primary immune response.

M. Mesri, A. Chapoval, F. Boldog, 2013, Molecular immunology.

Differential Induction of Apoptosis by Fas–Fas Ligand Interactions in Human Monocytes and Macrophages

P. M. Davis, P. Kiener, J. Ledbetter, 1997, The Journal of experimental medicine.

Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation.

P. M. Davis, P. Kiener, J. Ledbetter, 1997, Journal of immunology.

Promotion of activated human B cell apoptosis and inhibition of Ig production by soluble CD95 ligand: CD95-based downregulation of Ig production need not culminate in activated B cell death.

P. Casali, P. Kiener, W. Stohl, 2000, Cellular immunology.

Retinoic acid and vitamin E modulate expression and release of CD178 in carcinoma cells: consequences for induction of apoptosis in CD95-sensitive cells.

P. M. Davis, P. Kiener, A. Aruffo, 2001, Experimental cell research.

The Membrane-proximal Scavenger Receptor Cysteine-rich Domain of CD6 Contains the Activated Leukocyte Cell Adhesion Molecule Binding Site (*)

B. Modrell, A. Aruffo, G. Starling, 1995, The Journal of Biological Chemistry.

Structure and chromosomal location of the human CD6 gene: detection of five human CD6 isoforms.

N. Nowak, T. Shows, A. Aruffo, 1997, Journal of immunology.

Selection of an unrelated donor for marrow transplantation facilitated by the molecular characterization of a novel HLA-A allele.

J. Hansen, C. Anasetti, S. Choo, 1993, Human immunology.

Homology-Based Genomic Mining of Growth Factors Implicated in Neoplasia and Nephritides

G. Starling, G. Ara, W. Larochelle, 2005 .

Inhibition of in vitro and in vivo T cell responses by recombinant human Tim-1 extracellular domain proteins.

R. Shimkets, M. Mesri, A. Chapoval, 2006, International immunology.

Soluble CD137 (4-1BB) Ligand Is Released Following Leukocyte Activation and Is Found in Sera of Patients with Hematological Malignancies1

P. Kiener, H. Salih, G. Starling, 2001, The Journal of Immunology.

Constitutive Expression of Functional 4-1BB (CD137) Ligand on Carcinoma Cells1

F. Lee, P. Kiener, A. Aruffo, 2000, The Journal of Immunology.

PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis

H. Kwon, D. Chao, B. '. ’t Hart, 2013, Arthritis Research & Therapy.

Epstein-Barr viral DNA in acute large granular lymphocyte (natural killer) leukemic cells.

M. Rowe, G. Starling, E. Deacon, 1992, Blood.

Serum Levels of CD137 Ligand and CD178 are Prognostic Factors for Progression of Myelodysplastic Syndrome

P. Kiener, H. Salih, C. Denzlinger, 2004, Leukemia & lymphoma.

Intercellular adhesion molecule‐3 is the predominant co‐stimulatory ligand for leukocyte function antigen‐1 on human blood dendritic cells

J. Fawcett, D. Simmons, W. Egner, 1995, European journal of immunology.

CD6-ligand interactions: a paradigm for SRCR domain function?

B. Haynes, J. Bajorath, D. Patel, 1997, Immunology today.

Expression of the CMRF-35 antigen, a new member of the immunoglobulin gene superfamily, is differentially regulated on leucocytes.

D. Jackson, J. McKenzie, G. Starling, 1993, Immunology.

Characterization of mouse CD6 with novel monoclonal antibodies which enhance the allogeneic mixed leukocyte reaction

A. Aruffo, A. Farr, G. Starling, 1996, European journal of immunology.

Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model

D. Chao, G. Starling, D. Law, 2009, Journal of Neuroimmunology.

Differential susceptibility to CD95 (Apo-1/Fas) and MHC class II-induced apoptosis during murine dendritic cell development

R. Gold, P. Kiener, E. Bröcker, 2000, Cell Death and Differentiation.

TRU-016, An Anti-CD37 SMIP™ Biologic, In Combination with Other Therapeutic Drugs In Models of Non-Hodgkin's Lymphoma

J. Byrd, D. Chao, G. Starling, 2010 .

(CD137) Ligand on Carcinoma Cells Constitutive Expression of Functional 4-1BB

F. Lee, P. Kiener, P. Trail, 2013 .

Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells.

B. Hock, G. Starling, D. Hart, 1994, Immunology.

Characterization of mouse ALCAM (CD166): the CD6‐binding domain is conserved in different homologs and mediates cross‐species binding

J. Bajorath, J. Kobarg, A. Aruffo, 1997, European journal of immunology.

Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.

J. Barrish, W. Pitts, A. Watson, 2005, Bioorganic & medicinal chemistry letters.

Malignanciesin Sera of Patients with Hematological Following Leukocyte Activation and Is Found Soluble CD137 (4-1BB) Ligand Is Released

P. Kiener, H. Salih, G. Starling, 2001 .

Identification of the tumor antigen 90K domains recognized by monoclonal antibodies SP2 and L3 and preparation and characterization of novel anti-90K monoclonal antibodies.

N. Tinari, S. Iacobelli, A. Aruffo, 1997, Biochemical and biophysical research communications.

A novel HLA-A*8001 allele identified in an African-American population.

J. Hansen, S. Choo, G. Starling, 1994, Human immunology.

Isolation of human blood dendritic cells by discontinuous Nycodenz gradient centrifugation.

G. Starling, A. McLellan, D. Hart, 1995, Journal of immunological methods.

Molecular cloning of a novel member of the immunoglobulin gene superfamily homologous to the polymeric immunoglobulin receptor

J. Bell, D. Jackson, G. Starling, 1992, European journal of immunology.

CD45 molecule cross-linking inhibits natural killer cell-mediated lysis independently of lytic triggering.

G. Starling, D. Hart, 1990, Immunology.

Inhibition of natural killer-cell mediated cytolysis with monoclonal antibodies to restricted and non-restricted epitopes of the leucocyte common antigen.

J. McKenzie, G. Starling, D. Hart, 1987, Immunology.

Modeling Hepatocellular Toxicity of Enavatuzumab, a Humanized Anti-TweakR Antibody

D. Chao, S. Rhodes, G. Starling, 2017 .

Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb

D. Chao, E. Hsi, Shiming Ye, 2012, Journal of Cancer Research and Clinical Oncology.

Superantigen-driven, CD8+ T cell-mediated down-regulation: CD95 (Fas)-dependent down-regulation of human Ig responses despite CD95-independent killing of activated B cells.

P. Kiener, W. Stohl, D. Lynch, 1998, Journal of immunology.

CD 95-Independent Killing of Down-Regulation of Human Ig Responses Down-Regulation : CD 95 ( Fas )-Dependent T Cell-Mediated + Superantigen-Driven , CD 8

P. Kiener, W. Stohl, D. Lynch, 1998 .

New molecules on dendritic cells and their interactions with T lymphocytes.

D. Simmons, B. Hock, J. McKenzie, 1995, Advances in experimental medicine and biology.

Identification of Amino Acid Residues Important for Ligand Binding to Fas

Jürgen Bajorath, Jeffrey A. Ledbetter, Alejandro Aruffo, 1997, The Journal of experimental medicine.

The Ly-1.1 and Ly-1.2 epitopes of murine CD5 map to the membrane distal scavenger receptor cysteine-rich domain.

A. Aruffo, G. Starling, G. Whitney, 1997, Tissue antigens.

Hairy Cell Leukemia Cells are Relatively Nk‐Insensitive Targets

G. Starling, D. Hart, J. Nimmo, 1988, Pathology.

Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab

A. Willingham, R. Kastelein, S. Sadekova, 2020, Molecular Cancer Therapeutics.

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

Don M. Benson, C. Hofmeister, H. Kwon, 2013, Cancer Immunology, Immunotherapy.

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

Michael D. Robbins, D. Chao, G. Starling, 2014, Cancer Immunology, Immunotherapy.

Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death.

P. Kiener, J. Huang, A. C. Knapp, 2000, Atherosclerosis.

The effect of elotuzumab on natural killer (NK) cell function against multiple myeloma (MM).

H. Kwon, D. Benson, G. Starling, 2011, Journal of Clinical Oncology.

Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR

D. Chao, Minhtam Doan, G. Starling, 2014, Front. Immunol..

Inhibition of non-MHC-restricted cytotoxicity by CD45 but not CD3 monoclonal antibodies in patients with large granular lymphoproliferative disease.

G. Starling, D. Hart, M. Beard, 1989, Clinical and experimental immunology.

Differential Induction of Apoptosis by Fas–Fas Ligand Interactions in Human Monocytes and Macrophages

P. M. Davis, P. Kiener, J. Ledbetter, 1997, The Journal of experimental medicine.

Natural killer (NK) cell activation, cytokine production, and cytotoxicity in human PBMC/myeloma cell co-culture exposed to elotuzumab (Elo) alone or in combination with lenalidomide (Len).

G. Starling, A. Rice, Rui Yun, 2012 .